Pishvaian MJ, Lee MS, Ryoo B, et al. Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). ESMO 2018, abstract LBA26.
Adjuvant anti-PD1 bij melanoom heeft impact op kwaliteit van leven
apr 2024 | Dermato-oncologie